[breadcrumb_custom]

Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Is The Most Intriguing Stock Today.

In the last trading session, 0.78 million Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) shares changed hands as the company’s beta touched 1.29. With the company’s per share price at $9.60 changed hands at $0.34 or 3.67% during last session, the market valuation stood at $936.67M. CNTA’s last price was a premium, traded about 2.08% off its 52-week high of $9.40. The share price had its 52-week low at $3.00, which suggests the last value was 68.75% up since then. When we look at Centessa Pharmaceuticals plc ADR’s average trading volume, we note the 10-day average is 0.88 million shares, with the 3-month average coming to 2.64.

Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information

Instantly CNTA was in green as seen at the end of in last trading. With action 17.79%, the performance over the past five days has been green. The jump to weekly highs of 9.95 added 3.67% to the stock’s daily price. The company’s shares are showing year-to-date upside of 20.60%, with the 5-day performance at 17.79% in the green. However, in the 30-day time frame, Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) is 38.93% up. Looking at the short shares, we see there were 1.11 million shares sold at short interest cover period of 4.18 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Centessa Pharmaceuticals plc ADR (CNTA) estimates and forecasts

Data shows that the Centessa Pharmaceuticals plc ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 43.93% over the past 6 months, a 29.44% in annual growth rate that is considerably higher than the industry average of 11.60%.

The 2024 estimates are for Centessa Pharmaceuticals plc ADR earnings to increase by 29.61%.

CNTA Dividends

Centessa Pharmaceuticals plc ADR is expected to release its next quarterly earnings report in March.

Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 2.01% of Centessa Pharmaceuticals plc ADR shares while 86.00% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 87.76%. There are 86.00% institutions holding the Centessa Pharmaceuticals plc ADR stock share, with Medicxi Ventures Management (Jersey) Ltd the top institutional holder. As of Sep 29, 2023, the company held 20.50% of the shares, roughly 19.96 million CNTA shares worth $129.16 million.

General Atlantic, L.P. holds the second largest percentage of outstanding shares, with 9.94% or 9.68 million shares worth $59.93 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Aug 30, 2023 were Fidelity Select Portfolios – Biotechnology and Price (T.Rowe) New Horizons Fund. With 2.79 million shares estimated at $21.02 million under it, the former controlled 2.86% of total outstanding shares. On the other hand, Price (T.Rowe) New Horizons Fund held about 1.04% of the shares, roughly 1.01 million shares worth around $6.26 million.

On Key

Related Posts